SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer
Duygu Duzgun, William Read, Sebastian Oltean
This study identifies SRPK1 as a key regulator of docetaxel resistance in prostate cancer by modulating splicing and apoptosis pathways.
bioRxiv · Sep 17, 2026 · PreprintCancer Biology